Taisha HALTED and reOPEN -25%
Update Neurogene:
Neurogene Announces First Patient Dosed in High-Dose Cohort of NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
High-dose NGN-401 has been well-tolerated, and low-dose NGN-401 continues to show a favorable safety profile
Interim safety data presented at the International Rett Syndrome Foundation (IRSF) ASCEND Summit
https://ir.neurogene.com/news-relea...-first-patient-dosed-high-dose-cohort-ngn-401
Taisha HALTED and reOPEN -25% Update Neurogene: Neurogene...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.48 |
Change
0.160(1.04%) |
Mkt cap ! $1.978B | |||
| Open | High | Low | Value | Volume |
| $15.10 | $15.48 | $15.04 | $6.154M | 402.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1498 | $15.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 8296 | 2 |
View Market Depth
| Last trade - 16.10pm 21/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |